Korro Bio, Inc. (NASDAQ:KRRO)
| Market Cap | 102.17M-77.1% |
| Revenue (ttm) | 2.38M-62.1% |
| Net Income | -106.64M-16.7% |
| EPS | -10.01-2.7% |
| Shares Out | 9.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,875 |
| Open | 10.36 |
| Previous Close | 10.49 |
| Day's Range | 10.21 - 10.46 |
| 52-Week Range | 5.20 - 55.89 |
| Beta | 2.36 |
| Analysts | Buy |
| Price Target | 15.00(+46.13%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About KRRO
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KRRO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KRRO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KRRO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KRRO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New KRRO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KRRO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KRRO
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $2.84M |
| VTIVanguard Morningstar Total Stock Market ETF | $2.44M |
| VXFVanguard Extended Market ETF | $879.54K |
| VTWOVanguard Russell 2000 ETF | $799.88K |
| LFSCF/M Emerald Life Sciences Innovation ETF | $676.02K |
| VHTVanguard Health Care ETF | $357.23K |
Estimated from each fund’s disclosed top holdings × AUM
KRRO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from KRRO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score